Yatiri Bio Inc. is pleased to announce a research collaboration agreement in Acute Myeloid Leukemia (AML) with Dr. Derek Stirewalt from the Fred Hutch Cancer Center (FHCC). This work will center around the discovery of novel AML prognostic and predictive biomarkers, as well as unique targets to drive a new era of therapeutic discovery.

Dr. Stirewalt has been a member of Fred Hutch’s transplant program for over 20 years and routinely oversees the care of patients receiving either an autologous or allogeneic transplant. His group was one of the first to examine the clinical significance of FLT3 mutations in AML. More information about Dr. Stirewalt and his work can be found at https://www.fredhutch.org/en/faculty-lab-directory/stirewalt-derek.html.

FHCC is a leading cancer center established in 1975 whose mission is to discover new ways to prevent, detect, and treat cancer and other diseases. They have helped more than 1.3M people who have benefited from bone marrow transplantation, a treatment that was pioneered and developed at FHCC. FHCC is currently running multiple clinical trials aimed at finding new treatments for AML and discovering new ways to use current AML treatments.